Patent classifications
A61K31/438
Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
The present invention relates to a combination product and its use in therapy.
Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X′, Y, Y′, A, A′, Q.sup.1, Q.sup.2, R.sup.1-R.sup.4, X.sup.4, R.sup.5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof. ##STR00001##
Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X′, Y, Y′, A, A′, Q.sup.1, Q.sup.2, R.sup.1-R.sup.4, X.sup.4, R.sup.5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof. ##STR00001##
Combinations for treatment of NASH/NAFLD and related diseases
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
Combinations for treatment of NASH/NAFLD and related diseases
The combination of (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide or pharmaceutically acceptable salt thereof, and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4′-piperidine]-1′-carbonyl)-6-methoxypyridin-2-yl)benzoic acid or pharmaceutically acceptable salt thereof, for treatment of diseases, including non-alcoholic steatohepatitis (NASH), in mammals are described herein.
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.
Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.
MUSCARINIC RECEPTOR AGONISTS
This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor and which are useful in the treatment of muscarinic M.sub.1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula
##STR00001##
where m, p, q, W, Z, Y, X.sup.1, X.sup.2, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.
MUSCARINIC RECEPTOR AGONISTS
This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor and which are useful in the treatment of muscarinic M.sub.1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula
##STR00001##
where m, p, q, W, Z, Y, X.sup.1, X.sup.2, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein.
SPIRO[3H-INDOLE-3,2'-PYRROLIDIN]-2(1H)-ONE COMPOUNDS AND DERIVATIVES AS MDM2-P53 INHIBITORS
The present invention encompasses compounds of formula (I) wherein the groups R.sup.1 to R.sup.7, A, V, W, X, Y, n, r and q are defined in claim 1, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.
##STR00001##